MWNA
FLNA

Marshall Wace North America’s Filana Therapeutics FLNA Stock Holding History

Marshall Wace North America’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-282,793
Closed -$12.7M – 1731
2021
Q1 		$12.7M Buy
+282,793
New +$11.1M 0.05% 349

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marshall Wace North America's FLNA Position: Q2 2021 in Review

Marshall Wace North America sold out of Filana Therapeutics (FLNA) in Q2 2021, closing a stake of 282,793 shares — an estimated $12.7M sold.

Marshall Wace North America first reported a position in FLNA in Q1 2021 and held it in 1 quarter. The position peaked at $12.7M in Q1 2021. 169 funds tracked by Wall St. Rank hold FLNA as of Q2 2021.

  • Marshall Wace North America reported no remaining Filana Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 282,793 Filana Therapeutics shares in Q2 2021, an estimated $12.7M.
  • Marshall Wace North America first reported a position in Filana Therapeutics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Filana Therapeutics position peaked at $12.7M in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.